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ABSTRACT 
Natural killer (NK) cells are part of our innate immune defence against virus-infected and 
transformed cells. Through a yet undefined mechanism, expression of inhibitory receptors for 
self-HLA class I molecules endow NK cells with increased functionality. The process leading 
to gain of function through inhibition is known as NK cell education.  In the first part of this 
thesis the cellular mechanisms behind this phenomenon were studied. We found that the 
expression levels of the activation/adhesion molecule DNAM-1 correlated with the education 
state in NK cells. Our results suggest that DNAM-1 together with coordinated conformational 
changes in the adhesion molecule LFA-1 may contribute to the heightened effector functions 
in educated NK cells. 
A decreased NK cell function has been previously associated with impaired immune 
surveillance and a higher risk for developing cancer. By studying samples from patients 
diagnosed with myelodysplastic syndromes (MDS), we found that NK cells in the bone 
marrow were phenotypically altered and functionally impaired. Two activating receptors, 
DNAM-1 and NKG2D were decreased, and the ability to recognise and kill MDS blast cells 
compromised. The phenotypic alterations correlated with the frequency of leukemic blast 
cells suggesting that the immune dysfunction progress with the severity of the disease. 
In one part of this thesis possibilities to improve tumour cell recognition by NK cells were 
examined. Oxidative stress induced by selenite in a tumour cell line lowered the surface 
expression of HLA-E, which is a ligand for inhibitory NKG2A receptors expressed by a large 
proportion of human NK cells. The downregulation of HLA-E led to increased NK cell 
detection and killing of the tumour cells by NKG2A+ NK cells. 
Therapeutic antibodies have led to a paradigm shift in the care of patients with malignant 
lymphoma. Yet the mechanisms of action and the contribution of discrete immune subsets to 
the clinical efficacy are largely unknown. One suggested mechanism is NK cell mediated 
antibody-dependent cellular cytotoxicity. We studied NK cell repertoires in sequential lymph 
node biopsies from follicular lymphoma patients undergoing treatment with anti-CD20 
antibodies. After treatment there was a decrease in peripheral NK cells, and the remaining 
NK cells from both peripheral blood and tumour-associated lymph nodes were activated. 
Furthermore, the NK cells showed an altered ability to produce cytokines after in vitro re-
stimulation. In conclusion, the data presented here provide new insights into how NK cells 
recognise and respond to tumour cells at steady state and in malignant diseases. 
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1 INTRODUCTION 
The immune system constitute of cells and molecules protecting our body against 
uncountable threats, including viruses, bacteria and sometimes our own cells behaving in an 
inappropriate way. The immune system can be divided into two arms, the innate and the 
adaptive arm. Components of the innate immune system respond broadly and rapidly to 
potentially dangerous challenges. The adaptive immune system is characterised by cells and 
effector molecules that mount a delayed, yet more specific response towards a pathogen, 
which involves development of a long-lasting memory so that our immune system can 
respond more efficiently to a second challenge. The human natural killer (NK) cell is a cell-
type traditionally considered part of the innate immune system, and is the main focus of this 
thesis. 
1.1 NATURAL KILLER CELLS 
NK cells are a type of white blood cells known for their ability to eliminate virus-infected or 
malignant cells and to secrete cytokines. The name ‘Natural Killer’ refers to the fact that 
these cells are ready to act and kill potential threats directly and without prior sensitisation (1, 
2). NK cells are found in our blood at frequencies around 5-15% of total lymphocytes, but 
also at varying numbers in other organs as in the bone marrow, secondary lymphoid organs, 
liver and uterus (3). 
1.1.1 Differentiation 
NK cells originate from hematopoietic stem cells (4). The stem cells differentiate into 
common lymphoid progenitors with maintained potential to become T cells, B cells or a 
variety of innate lymphoid cells (ILCs) (5). The lack of antigen specific receptors separates 
ILCs from the adaptive T- and B-lymphocytes (5). There are three main groups of ILCs 
described, with NK cells belonging to type 1 ILCs. (6) Cells in this group share features as 
expression of the transcription factors T-bet and Eomes, and effector functions as cytotoxicity 
and interferon (IFN)-γ cytokine production (7). Apart from NK cells, the different types of 
human ILCs have only recently been characterised, and the strict division between a human 
NK lineage progenitor and other closely related innate lymphoid cells is not clear (8).  
NK cells mature in the bone marrow, but precursors with ability to differentiate to mature NK 
cells have been found also in other organs as liver, tonsils and thymus (4, 9-13). Interleukin 
(IL)-15 is an essential cytokine for NK cell development, proliferation and survival (14). NK 
cells in peripheral blood are defined as CD3 negative and positive for the cell surface 
molecule CD56, expressed at either high (CD56bright) or medium (CD56dim) levels. It is not 
clear if CD56bright and CD56dim NK cells represent two different lineages, as supported by 
studies of haematopoiesis in macaques (15), or if CD56bright are the precursors of CD56dim 
cells. The CD56bright cells have shorter telomeres than CD56dim cells (16), and can acquire 
phenotypic similarities to CD56dim NK cells in vitro and in humanised mice (17, 18). 
CD56bright cells respond primarily to cytokine stimulation and are efficient cytokine producers 
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(19). Recently, it has become clear that the CD56dim subset is highly diversified in part 
through a continuous differentiation process (17, 20-22). The least mature cells have more 
similarities to the CD56bright cells and express higher level of cytokine receptors, NKG2A and 
natural cytotoxicity receptors (NCRs), and have a high proliferative capacity. The maturation 
process includes a loss of cytokine responsiveness, and acquisition of inhibitory killer cell 
immunoglobulin receptors and CD57, a cell surface marker correlated with senescence in T 
cells (23). Additionally, there is an increase of molecules associated with cellular 
cytotoxicity, as CD16, granzyme B and perforin (22). The most mature NK cell subsets are 
highly cytotoxic and efficient cytokine producers in response to activating receptor 
stimulation, including via antibody-coated cells (22, 24).  
Based on the cell surface receptor expression profile, the NK cell population is very 
heterogeneous, yet stable over time (25). One lasting influence on the NK cell repertoire is an 
infection with cytomegalovirus (CMV), which is correlated with an increased level of NK 
cells expressing an activating receptor CD94/NKG2C (25-32). CMV infection induces 
expansion of a memory NK cell subset in mice (33). This subset has an activating receptor, 
Ly49H that specifically recognise a mouse CMV-encoded peptide expressed on infected cells 
(33). Such antigen-specificity has not been found in human NK cells, although recent studies 
have shown NK cell subsets exhibiting adaptive immune features including stable epigenetic 
modifications (34-37).       
1.1.2 Receptors 
NK cells express numerous germline-encoded receptors on the cell surface, some are 
summarised in table 1.   
Inhibitory receptors 
The two major families of inhibitory NK cell receptors in humans are the heterodimer 
CD94/NKG2A and inhibitory killer cell immunoglobulin-like receptors (KIRs). 
CD94/NKG2A belongs to the C-type lectin receptors, and binds to HLA-E (38, 39). KIRs 
bind to specific allelic variants of HLA-A, -B and –C, encoding human major 
histocompatibility (MHC) class I molecules (40). As with the MHC class I gene locus, the 
KIR gene locus is highly polymorphic and on a population level numerous combinations of 
KIRs and allelic variants exists (41). Additionally, the KIR expression on individual NK cells 
differs despite identical gene content (42). 
The cytoplasmic domain of the inhibitory receptors contains immunoreceptor tyrosine-based 
inhibition motifs (ITIMs) (43). Upon binding to its HLA ligand the inhibitory signal is 
transmitted via ITIM phosphorylation and recruitment of phosphotyrosine or inositol 
phosphatases, which in turn can lead to decreased tyrosine phosphorylation of effectors in 
activation pathways (44). The inhibition prevents Ca2+ influx, actin rearrangements and 
formation of lipid rafts (45, 46). 
 
  3 
 
Table 1: NK cell receptors and their ligands 
Receptor  Ligand Function 
CD94/NKG2A HLA-E Inhibitory 
KIR2DL1 HLA-C2 Inhibitory 
KIR2DL2/3 HLA-C1 Inhibitory 
KIR3DL1 HLA- Bw4 Inhibitory 
KIR3DL2 HLA-A11/A3 Inhibitory 
KIR2DS1 HLA-C2 Activating 
KIR2DS2  Activating 
KIR3DS1  Activating 
CD16 IgG Activating 
CD94/NKG2C HLA-E Activating 
NKG2D ULBP, MICA/B Co-activating 
NKp30  B7-H6 Co-activating 
NKp44   Co-activating 
NKp46  Co-activating 
2B4 CD48 Co-activating 
DNAM-1 CD155, CD112 Co-activating, adhesion 
LFA-1 ICAM-1 Adhesion, granule polarisation 
 
Activating receptors 
Activating NK cell receptors generally require combinatory engagement in order to induce a 
cytotoxic or cytokine response to take place (47, 48). An exception is engagement of the low-
affinity Fc-receptor CD16, which binds antibody on target cells and is sufficient to induce 
NK cell degranulation (49). Activating receptors transmit the signals via cytoplasmic adaptor 
proteins and various signalling domain and pathways exists (50). 
CD16 associates with FcεRγ and CD3ζ adaptors, both carrying immunoreceptor tyrosine-
based activation motifs (ITAMs) (50). Receptor ligation leads to phosphorylation of the 
ITAMs by Src family-kinases, and engagement of SH2-domain containing signalling proteins 
that propagate activating signals (51). 
NKG2D is an activating receptor that binds to several ligands, including MICA, MICB and 
the ULBP family (52). These ligands are up-regulated on virus-infected cells, DNA damaged 
or transformed cells (53). Mice deficient in NKG2D have an increased tumour outgrowth, 
suggesting an important role for this receptor in tumour surveillance and elimination (54). 
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NKG2D associates with a DAP10 adaptor signalling protein, which has a tyrosine-based 
motif that can be phosphorylated upon activation for signalling transduction (55). 
DNAM-1, also known as CD226, is an activating and adhesion molecule (56). Similar to 
NKG2D it binds to stress-induced ligands, for DNAM-1 it is CD155 (PVR) and CD112 
(Nectin 2) (57). These ligands are commonly expressed at high levels on tumour cells, and 
DNAM-1 has been shown to have an essential part in immune surveillance (58-62). CD155 is 
also expressed on dendritic cells (DCs) and T cells, and the DNAM-1/CD155 interaction has 
been proposed to play a role in selective NK-cell mediated DC-editing during an immune 
response (63). The intracellular signalling downstream of DNAM-1 is not known, but the 
receptor can functionally and physically associate with lymphocyte function-associated 
antigen-1 (LFA-1) (64). 
Adhesion molecules 
Adhesion molecules are important for NK cell trafficking to tissues as well as initiation and 
promotion of contact with target cells. One essential molecule in formation of conjugates 
between cells is LFA-1 (65). LFA-1 binds to intracellular adhesion-molecule-1 (ICAM-1), 
and this alone is sufficient in NK cells to induce an activating signal and polarise granules 
(49, 66). Stimulation through activating receptors leads to an inside-out signal to LFA-1 (67). 
This changes the conformation of LFA-1 to an open, active form that facilitates stable 
conjugate to be formed with ICAM-1 expressing cells (68). NK cells, in contrast to T cells 
(69), do not need an inside-out-signal to activate LFA-1, although the signal is required for 
further stable conjugate propagation, activation and granular release (50).  
1.1.3 Activation 
The stimulation of NK cells through activating receptors or cytokines can lead to cytotoxic 
response and production and release of cytokines and chemokines as IFN-γ, TNF-α and MIP-
1β (70). In contact with target cells, NK cells can form an immunological synapse with 
activating molecules clusters in the central part and adhesion molecules as LFA-1 in the 
peripheral part (71). Inhibitory and cytotoxic synapses have been shown to be formed in the 
same way in NK cells and differ in the ratio between activating tyrosine kinases and the 
tyrosine phosphatases in the central part of the conjugate (72-74). A high ratio will through 
signalling cascades ultimately lead to Ca2+ influx, re-organisation of actin cytoskeleton and 
delivery of lytic granules to the synapse via microtubule transport. The granules released in 
the cytotoxic synapse contain perforin, a pore forming protein, and granzymes, proteins 
capable of inducing apoptosis once entering the target cell (75). NK cells can furthermore 
upon ligation of ‘death receptors’, TRAIL and Fas-ligand, induce apoptosis in target cells 
(76). 
NK cells have receptors for type I interferons, and can be activated by the release of pro-
inflammatory cytokines as IL-12, IL-18 and TNF (77, 78). Signalling through cytokine 
receptors can lead to STAT phosphorylation and transcription, production and secretion of 
IFN-γ, an important mediator of pro-inflammatory and antiviral effects (79). The signalling 
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pathways for cytokine production and induction of cytotoxic responses are overlapping, and 
both cytokine activation of NK cells and stimulation through activating receptors can 
promote a cytotoxic response and induce cytokine production. (80)  
1.1.4 Functional regulation 
Missing-self-recognition 
The functional regulation of NK cells was in the 1980’s hypothesised as a missing-self 
recognition (81). In contrast to T cells, where activation occurs upon recognition of HLA 
class I molecules presenting non-self peptides, NK cells could detect and respond to cells that 
down-regulated or lacked expression of self-HLA class I molecules (82). Predictions made in 
the hypothesis were confirmed when the inhibitory KIRs in humans and Ly49 receptors in 
mice were identified and shown to bind self-expressed MHC class I molecules (83, 84). In 
addition to lack of inhibition, NK cells require activation signals to trigger a functional 
response (47).  
Education 
A more recently described role for inhibitory receptors is to tune the threshold for activation 
and determine the functional capacity of the cell in a process referred to as ‘education’ (85). 
In order to develop highly efficient effector functions NK cells need to express at least one 
type of inhibitory receptor recognising self-expressed HLA molecules. It remains unknown 
how the inhibitory signal in NK cells is translated to an increased functional competence in 
terms of cytotoxicity and cytokine production upon activation. Several models to explain NK 
cell education have been proposed. In the disarming model all cells are initially fully 
competent and require the inhibitory input to maintain their functionality (86, 87). In the 
arming model, cells acquire the increased effector function along with self-inhibitory 
receptors during development (88, 89). Compatible with both models, more recent data 
suggests that education is not an on and off switch (90). Instead the NK cell function can be 
likened to a rheostat, being adjusted depending on the MHC class I environment and the 
amount of inhibitory interactions the cell receives (90). 
1.2 TUMOUR CELLS 
A normal cell can transform into a tumour cell and ultimately cause severe damage to the 
body. For this to occur the shared hallmarks described are; sustained proliferative capacity, 
evasion of growth suppressors, induction of angiogenesis, activating invasion and metastasis, 
enabling of replicative immortality, resistance to cell death, reprogrammed energy 
metabolism and evasion of immune destruction (91). Tumour cells are an enormously 
heterogeneous population and this section will briefly introduce two human diseases of 
particular relevance for paper II and IV. 
1.2.1 Myelodysplastic syndromes 
Myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders in the 
bone marrow (92). Mainly older adults are diagnosed with MDS and median age at diagnosis 
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is 76 years (93). The cause of MDS is mainly unknown, but in approximately 15% of the 
cases it is associated to earlier use of radiotherapy, chemotherapy, tobacco smoking or 
exposure to benzene. (92) The disease is characterised by ineffective haematopoiesis and 
cytopenias as a consequence from increased apoptosis in myeloid progenitors (94). One third 
of the MDS patients progress to acute myeloid leukemia (AML), with high frequencies of 
myeloblasts (>20%) (95). A shift from apoptosis to proliferation in the progenitors may be 
one factor that result in progression to AML (96, 97). One type of MDS is the 5q syndrome, 
where a variable number of genes have been deleted on the 5q chromosome (98). This can 
lead to blocked erythroid proliferation due to reduced gene expression of RPS14 (99, 100), 
and other defects reflecting the loss of genes.  
The cell expansion in MDS is often oligoclonal with several different types of gene mutations 
contributing to the pathogenesis (92). These mutations are frequently affecting genomic 
stability and gene expression patterns and include mutations in transcription factors, 
epigenetic regulators involved in methylation of cytosines or histone modifications (101). 
Some of the most recurrently mutated genes are: TP53, ETV6, DNMT3A, TET2, IDH1, IDH2, 
EZH2, UTX, ASXL1 (92). Other frequently mutated genes encode parts of the splicing 
machinery, which may have several functional consequences including disruption of genomic 
stability (102, 103). Somatic mutations are of prognostic value and mutations in TP53, ETV6, 
RUNX1 or EZH2 effects survival and worsen the prognosis (104, 105). Some epigenetic 
changes as aberrant methylation of gene promoters have been seen in MDS (92). 
Furthermore, the microenvironment and immune cells may contribute to the disease 
progression and increased numbers of T regulatory cells (Tregs) have been seen in patients 
with high-risk MDS (106). 
The treatment of MDS is primarily dependent on disease severity (92). Treating high-risk 
patients with a median survival of 12 months aim to prolong survival, avoid AML and 
modify the disease progression. The group of patients with low or intermediate risk is treated 
mainly to improve the cytopenia as well as quality of life, since many of these patients will 
not die from their MDS. Lower-risk MDS patients generally receive erythropoiesis-
stimulating agents, but many will eventually though need erythrocyte transfusions. For high-
risk MDS, the only cure is allogeneic stem-cell transplantation. However, there is a high risk 
of transplant-related mortality and only a few patients can be offered this treatment. 
Chemotherapy, similar to treatment for AML, can be suitable for patients younger than 65 
years and with favourable cytogenetics, sometimes as pre-treatment to transplantation. 
Clinical trials have found a survival benefit and delayed progression to AML using 
azacitidine, a hypomethylating agent in high-risk MDS, compared to supportive care or 
chemotherapy (107). However, even if the median survival is prolonged with azacitidine it is 
still only 2 years, and several combinations of drugs are currently being examined (92).     
1.2.2 Follicular lymphoma 
Follicular lymphoma (FL) is a B cell disease originating in lymph node germinal centres 
(108). A germinal centre in FL resembles a healthy follicle, with follicular DCs, macrophages 
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and T cells supporting the growth of B cells (109). 90% of all follicular lymphomas have a 
chromosomal translocation t(14;18), leading to over-expression of an anti-apoptotic Bcl-2 
protein (110, 111). Increased Bcl-2 expression gives the lymphoma cells a survival 
advantage, but similar to normal B cells in the germinal centre, they are dependent on 
surrounding cells for development (112). The FL progression towards additional genetic 
abnormalities might be facilitated by excessive Bcl-2 protein expression (113). Another 
alteration, observed in 89% of FL’s is a mutation in MLL2, a gene encoding a histone 
methyltransferase (114). This can impair cell transcription but the exact consequences of this 
are still unknown. Studies have shown that an increase of CD8+ T cell infiltrate in FL 
correlates to better prognosis (115, 116). Furthermore, gene expression profiling revealed that 
mostly T cell related genes were linked with favourable prognosis, while genes expressed by 
macrophages were associated with poor prognosis (117). The composition of cells in the 
tumour environment is thought to have a prognostic role, but many studies have so far shown 
inconsistent results, possibly due to different treatment protocols (117).  
Since 1998, a cornerstone of FL therapy is rituximab, a monoclonal antibody recognising the 
CD20 antigen expressed on mature B cells (118). This is administrated alone or in 
combination with chemotherapy (119). Most patients respond well, but the relapse rate is 
high and the disease considered incurable (120). Furthermore, 25% of the patients experience 
transformation of the disease to a more aggressive form of B cell lymphoma, requiring 
intense chemotherapy (121). The median survival in FL is 13 years (122).  
The use of monoclonal antibodies as rituximab can have several effects (123). Binding of 
CD20 itself to malignant B cell lines is sufficient to induce cell death in vitro (124). Other in 
vitro studies have shown complement-dependent cytotoxicity for rituximab (125, 126), 
although the role of components from the complement system within lymph nodes is 
unknown. The third mechanism of action for rituximab is through ADCC mediated by NK 
cells, and/or antibody-dependent cellular phagocytosis mediated by macrophages (127, 128). 
NK cells engage the CD16 receptor to the Fc-part of antibody bound to target cells. This 
triggers strong NK cell activation including release of cytotoxic granules and production of 
pro-inflammatory cytokines as IFN-γ (67). The clinical response to rituximab therapy 
correlates to polymorphisms in the CD16 gene, supporting a role for NK cell involvement 
(127, 129, 130). 
1.3 CANCER IMMUNOEDITING 
The immune system can shape and control cancer outgrowth. In addition, tumour cells 
interact with and influence their surroundings, with defective immune responses being 
reported in many cancer types (131). The term cancer immunoediting describes the process 
where the immune system prevents or promotes cancer progression (132). It is subdivided 
into three phases; elimination, equilibrium and the escape phase.  
Originally the term cancer immunosurveillance was used to explain the protection against 
tumour development by the immune system (133). This hypothesis was criticised due to lack 
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of convincing experimental data supporting immune-mediated control of non-viral tumours. 
However, lessons from several different studies in mice lacking distinct immune components, 
including perforin, IFN, T- and B-cell receptors as well as T cells, B cells, NKT cells, γδ T 
cells, NK cells, monocytes and macrophages, are that the immune system do in fact control 
induced and spontaneously formed cancer types (134). Transferring cells from wildtype (wt) 
mice to immunocompromised mice and vice versa revealed how tumour cells were shaped 
(edited) by its surrounding, and the need of a broader definition for the interactions between 
cancer and the immune system (135, 136). Cancer immunosurveillance occurs during the 
elimination phase of immunoediting (137). This phase is followed by a longer equilibrium 
phase during which the immune system edits the phenotype of the tumour. Immune selection 
pressure during the equilibrium phase favours the outgrowth of non-immunogeneic escape 
variants during the third and final phase of immunoediting, the escape phase. 
In the elimination phase, several immune effector molecules, including type I IFNs, IFN-γ, 
perforin, Fas-L and TRAIL have been shown to be important for protecting the host against 
neoplastic transformation (134). All nucleated cells can produce type I IFNs and studies using 
neutralising antibodies against type I IFNs or blocking type I IFN receptor have shown 
increased tumour growth and metastasis in mice (138). NK cells, T cells and NKT cells can 
produce IFN-γ (139). Similarly to type I IFNs, IFN-γ neutralising antibodies increase cancer 
development in mice (134). Furthermore, animals lacking a subunit of the IFN-γ-receptor or 
being IFN-γ-deficient, more frequently developed induced sarcoma and lymphoma compared 
to wt mice (135, 140-142). The source of IFN-γ in elimination of cancer is not known, but γδ 
T cells are suggested as an important producer (143). Mice lacking the activating NK cell 
receptors NKG2D and DNAM-1 display impaired control of tumour growth (54, 61), 
indicating the NK cell recognition of tumour cells is also important. 
If the immune system fails to eradicate the malignant cells, the result can be outgrowth of 
tumour cells less recognisable by the immune cells, which are either hiding quietly or 
progressing to a more aggressive form. In maintaining a hidden equilibrium phase between 
the immune system and cancer, associations are made to the different proportions of immune 
cells and to the cytokine balance, where e.g. IL-12 and IFN-γ promote tumour cell 
elimination while IL-23 and IL-10 promote persistence (144).  
The escape phase is characterised by reduced tumour cell recognition by immune cells, an 
increased tumour cell survival and development of an immunosuppressive environment by 
the tumour cells (132). 
1.3.1 Tumour escape from NK cells 
A decreased NK cell function has been associated with a higher risk for developing cancer 
(145). Moreover, dysfunctional NK cells have been described in different types of cancer 
diseases (146). This can be due to exhausted and desensitised NK cells, or factors secreted by 
the tumour cells facilitating avoidance of NK cell recognition and an impaired NK cell 
function (131). Inhibitory molecules produced by tumour cells can be cytokines as the 
transforming growth factor beta (TGF-β) (147). TGF-β can reduce NK cell activity, and this 
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has been linked to a reduced expression of NKp30 and NKG2D (148). Microvesicles from 
tumour cells can contain immunosuppressive components as microRNA and cytokines (149, 
150). In AML patients such vesicles were found to contain TGF-β that modulated NKG2D 
expression and NK cell function (151). AML cells have in another study been shown to up-
regulate CD200, a cell surface glycoprotein that interfered with NK cell function (152). Other 
factors affecting the NK cells are production of reactive oxygen species (ROS), and 
monocytic and myelo-monocytic AML cells could this way trigger NK cell apoptosis (153). 
Tumour cells can furthermore create a milieu promoting tumour growth while suppressing 
immune surveillance. Cancer cells can this way indirectly influence NK cells and NK cell 
function by recruitment and support of immunosuppressive cells as Tregs, type 2 
macrophages and myeloid derived suppressor cells (154).  
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2 AIMS 
 
I. Study cellular mechanisms underlying functional tuning of NK cells at steady state 
 
II. Characterise the integrity of NK cell phenotype and function in patients with 
myelodysplastic syndromes 
 
III. Explore possibilities to improve tumour cell recognition through modulation of the 
redox status 
 
IV. Examine dynamics of NK cell repertoires and function during monoclonal antibody 
therapy for follicular lymphoma 
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3 RESULTS AND DISCUSSION 
3.1 ACTIVATION AND ADHESION IN EDUCATED NK CELLS  
NK cell activation is regulated by signals from activating and inhibitory cell surface 
receptors. Besides this, the intrinsic functional capacity of NK cells to respond varies. NK 
cells expressing an inhibitory receptor binding to a self-expressed HLA class I molecule have 
been shown able to respond stronger than cells lacking this inhibitory input, this is referred to 
as NK cell education or licensing (88, 155). The mechanism behind this is not fully 
understood and comparisons of educated and non-educated NK cells have failed to explain 
any major differences on a transcriptional and cellular level (155, 156). It has been suggested 
that the educated cells differ in organisation of receptors in the immunological synapse 
formed upon target interaction, which furthermore influence conjugate formation and 
functional responses (156, 157). 
In paper I, we focused on activating and adhesion molecules on NK cells, finding a 
correlation between expression levels of the activating receptor DNAM-1 and cellular 
education. An earlier comparison has shown differential DNAM-1 levels on KIR+NKG2A+ 
versus KIR-NKG2A- NK cells (155). Confirming and extending these results, we observed 
increased expression on cells having self-inhibitory KIR receptors compared to cells 
expressing non-self inhibitory KIRs. Additionally we found the more differentiated CD57+ 
NK cells to have an amplified level of DNAM-1 and the number of educating receptors on 
the cell surface to correlate with DNAM-1 expression. The differentiation process in NK cells 
is linked to accumulation of KIRs, increased CD16 and granzyme B expression and gain of 
cell surface CD57, as well as an increased cytolytic capacity (21, 22). The higher level of 
DNAM-1 in more differentiated NK cells expressing CD57 and multiple KIRs as well as the 
more immature NK cells expressing 
NKG2A including CD56bright cells, 
suggests that the inhibitory 
interactions are important for 
maintained DNAM-1 expression on 
the cell surface (Figure 1).  
 
 
Figure 1: High DNAM-1 expression 
correlates with inhibitory educating KIR and 
NKG2A receptors. Median fluorescent 
intensity of DNAM-1 on the indicated NK cell 
subsets. Donors are HLA-C1+/C2+. The cells 
are negative for NKG2C, KIR3DL2, 
KIR2DS4, KIR3DL1 and activating KIRs. 
(N=16).  
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Previous findings have revealed down-regulation of DNAM-1 on NK cells upon physical 
interactions with the ligand CD155 (158). In Cd155-deficient mice, T cells and NK cells 
display increased DNAM-1 expression, which decreases if the cells are transferred to a WT 
mouse with normal CD155 levels (159).  
CD155 is an immunoglobulin-like transmembrane protein involved in cell-cell adhesions and 
cell motility, and it is expressed on fibroblasts, epithelia, endothelia and hematopoietic cells 
including dendritic cells (DCs) and T cells (57). Interestingly DCs but not other T cells or 
stromal cells could modulate DNAM-1 expression in vivo on mouse T cells (159) and the 
negative selection of CD8+ T cells in thymus was impaired in DNAM-1 knockouts as well as 
animals lacking CD155, suggesting the DNAM-1/CD155 interaction is important to obtain 
mature CD8+ T cells (160). During NK cell maturation the contact with DCs or other CD155+ 
cells might thus regulate the level of DNAM-1 on the NK cell surface, assuring that only cells 
which are competent to distinguish between self and non-self via inhibitory HLA class I-
binding receptors can retain high DNAM-1 expression (Figure 2). 
 
 
 
Figure 2: High DNAM-1 levels explained by inhibitory interactions. 1: Educated NK cell in contact with 
CD155+ cell, where signalling through inhibitory receptors prevent activation. Lack of inhibition facilitates 
DNAM-1/CD155 binding in non-educated NK cell. 2: Cell contact ends and the educated NK cell have 
continued high DNAM-1 expression. The non-educated and hypo-responsive NK cell may down-regulate 
DNAM-1 after interaction with the ligand.    
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1
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Most assays used to examine NK cell function involve activation through DNAM-1 since 
several common target cell lines express the ligands CD155 and CD112. Therefore it its not 
surprising that cells expressing higher DNAM-1 levels also respond better to stimulation with 
CD155/CD112+ target cells. In our experiments we could see a clear correlation between 
functional response to target cell stimulation and the DNAM-1 expression, but independently 
if the target cell expressed the DNAM-1 ligands or not. DNAM-1 can physically associate 
with the adhesion molecule LFA-1 on the cell surface (64). To find out if the LFA-1/ICAM-1 
interaction was responsible for the higher response also in CD155/CD112 negative cells, we 
used a reductionistic model system where we co-incubated NK cells with insect cells (at 
baseline lacking ligands to human NK cells) transfected with specific NK cell receptor 
ligands. Activation of NK cells in the absence of LFA-1 and DNAM-1 ligands displayed 
sustained correlation of the functional response and DNAM-1 expression. This suggests the 
DNAM-1 expression level is an intrinsic marker for NK cells with a high capacity to preform 
cytotoxic and cytokine response upon contact with tumour cells. 
One initial step in conjugate formation between cells is a conformational change of the LFA-
1 molecule into its open, active form enabling an immune synapse formation and killing of 
the target cell (49, 68, 161, 162). By detecting the active form of LFA-1, we could see an 
increased frequency of this form after cytokine stimulation. Similar data has previously been 
described following stimulation with target cells (48). Cytokine stimulation mainly affected 
non-educated cells to change their LFA-1 conformation while LFA-1 in educated NK cells 
was kept in tight control by the inhibitory receptors (Figure 3). In contrast, stimulation of NK 
cells with HLA class I negative target cells on the other hand resulted in higher frequency of 
educated cells expressing an active LFA-1 conformation.  
 
Figure 3: LFA-1 is activated mainly on non-educated NK cell upon cytokine stimulation, while LFA-1 on 
educated cells are kept in a closed inactive form by the inhibitory receptor interactions.   
HLA class Iself-KIR
LFA-1 active LFA-1 ICAM-1
non-educated educated
Cytokines
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Studying the mobilisation of LFA-1 and DNAM-1 to the immunological synapse we found 
DNAM-1 to polarise even in the absence of its ligands on the target cell, although at a lesser 
degree compared to when the ligands were present. This recruitment suggests an outside-in 
signalling event enabling LFA-1 to activate and co-localise DNAM-1. 
In an inhibitory immune synapse, KIR receptors binding to HLA class I accumulate in the 
middle, surrounded by LFA-1 molecules (163, 164). It is not known if DNAM-1 can be 
found in an inhibitory conjugate synapse or more peripheral. In stimulatory settings on lipid 
bilayer activating receptors have been shown segregated into different areas, 2B4 interacting 
at the centre while NKG2D in a peripheral region and co-localised with LFA-1 (165). Guia et 
al compared hypo-responsive to educated NK cells, and inhibitory receptors were found 
positioned in a cytoskeleton-based meshwork in both cases (156). The activating receptor 
NKp46 was found in similar meshwork as the inhibitory receptors in hypo-responsive cells, 
while in educated cells NKp46 was localised in signal-favouring, lipid dependent 
nanodomains and separated from inhibitory KIRs (156). In another study educated NK cells 
formed more conjugates and killing events compared to inhibitory receptor negative cells. 
This was not due to differences in LFA-1 itself but instead enhanced inside-out signals to 
LFA-1 by activating receptors, causing more stable adhesion in conjugate with the target cell 
(157). Conclusions from our studies suggests that DNAM-1 and LFA-1 mobilising at the 
immune synapse can contribute to the heighten effector functions in educated cells (Figure 4). 
 
 
Figure 4: DNAM-1/LFA-1 at the immune synapse may contribute to strong activation in educated cells. 
Educated NK cells with high DNAM-1 expression facilitate strong activation including increase of active LFA-
1. Non-educated cells have less DNAM-1 leading to less active LFA-1 and a weak NK cell activation. Non-
educated cell pre-activated with cytokines have low DNAM-1 but increased active LFA-1 and can therefore 
respond better compared to non-educated NK cells without cytokine stimulation.    
LFA-1 active LFA-1 ICAM-1
CytokinesDNAM-1 CD155NK cell
Tumour cell
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3.2 DEFECTIVE NK CELL CYTOTOXICITY RELATED TO DECREASED 
LEVELS OF ACTIVATING RECEPTORS 
In paper II we examined the NK cells in patients suffering from MDS. Previous research on 
MDS patients had shown reduced function and in some cases decreased receptor expression 
in peripheral blood NK cells (166-169). One study linked the peripheral blood NK cell 
function with the severity of the disease (166). MDS mainly affect the bone marrow and 
because of this we set out to investigate the function and phenotype of NK cells residing in 
the bone marrow.  
First, we examined the receptor expression on NK cells in MDS patients and age-matched 
healthy controls by flow cytometry. This revealed a decrease of two activating receptors on 
NK cells in MDS patients compared to controls, DNAM-1 and NKG2D. Since increased 
number of blasts in the bone marrow is associated with a worse clinical prognosis, we divided 
our cohort into patients with low or high frequencies. This stratification revealed a more 
distinct decrease of DNAM-1 and NKG2D in the patients with high blast counts (Figure 5).  
Figure 5: Reduced expression of DNAM-1 and NKG2D associated to high MDS blast frequencies. Receptor 
expression on bone marrow NK cells from healthy donors (HD) compared to MDS patients with low (<5%) or 
high (>5%) bone marrow blast count.     
 
There are different mechanisms described for how NK cell receptor expression can be 
altered. In addition to physical receptor-ligand interactions leading to receptor internalisation 
as discussed above for DNAM-1, receptors may also be shed or degraded. Other factors that 
can influence the receptor expression are cytokines and tumour-derived factors such as 
microvesicles, soluble ligands and ROS. (146) 
We examined the ligand repertoire on CD34+ blast cells in MDS patients and found ligands 
for DNAM-1 and 2B4 to be frequently expressed whereas NKG2D ligands were less 
common. By comparing tumour cells and NK cells separated in transwells, previous work 
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from our laboratory showed that DNAM-1 receptor down-regulation in ovarian carcinoma 
was dependent upon physical interaction with the ligand CD155 (158). In another study, 
AML patients had decreased DNAM-1 levels associated with ligand expression on the AML 
blast cells (170). Similar events might also be the cause of reduced DNAM-1 and NKG2D 
levels on NK cells in the bone marrow of MDS patients, given the correlation we found 
between high blast counts and loss of these activating receptors.    
Cytokines released in the tumour microenvironment can also affect NK cell receptor 
expression. TGF-β has previously been described to cause down-regulation of NKG2D 
expression on NK cells in MDS patients (171, 172). NKG2D has also been shown to be 
down-regulated due to ligand interactions (173-175). Furthermore, shed NKG2D-ligands may 
modulate the receptor expression and interfere with cytotoxic functions (176). In MDS 
patients, no soluble NKG2D-ligands have yet been reported, and in our study a minority of 
the patients had blast cells expressing NKG2D ligands. However, a recent study in mice 
(177) describes a more complex picture where tumour-associated macrophages desensitises 
NK cells through stimulating NKG2D by a membrane-bound ligand, while a soluble mouse 
NKG2D-ligand competes with this binding and counteract the functional impairment 
resulting in tumour growth inhibition. This mechanism to improve NK cell activity has to be 
further studied, but could potentially lead to new therapeutic strategies.  
We also examined the NK cell function in paper II by studying degranulation after 
stimulating NK cells with tumour target cells, or by activating specific receptors through a 
reversed antibody-dependent cytotoxicity (ADCC) assay, in addition to measurements of cell 
death in tumour cells after being in contact with NK cells.  
The degranulation of the patients’ NK cells showed a defect function in both peripheral and 
bone marrow NK cells. Furthermore, by blocking specific NK cell receptors and studying 
tumour cell death after co-incubation with healthy donor NK cells, a major impact of the 
DNAM-1 receptor was detected for recognition and killing of MDS tumour cells (Figure 6). 
In these experiments HLA class I molecules were blocked to restrict the analysis to activating 
signals in the NK cell upon contact with the tumour cells. Finally, a comparison using 
autologous or allogeneic bone marrow-derived NK cells confirmed a defect in NK cells with 
poor cytotoxic response towards MDS tumour cells in patients. 
 
Figure 6: Blocking DNAM-1 
receptor reduces killing of MDS 
blasts. Specific killing of bone 
marrow CD34+ blast cells from a 
MDS patient. The NK cells from 
healthy donors were HLA class I 
blocked in addition to blockade of 
specific activating receptors as 
indicated. 
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Our results suggest an important role for the DNAM-1 receptor in recognition and killing of 
CD34+ blast cells in MDS patients.  Other studies of MDS patients have shown dysfunctional 
NK cells in peripheral blood (166-169), and in one case without any connection to changed 
NK cell receptor levels. This was instead related to a genetic alteration carried by a 
proportion of NK cells as well as the CD34+ blast cell (168). MDS is a very heterogeneous 
disease and different mechanisms could be involved in the functional impairment of NK cells 
in peripheral blood and bone marrow. It is possible that for example also immunosuppressive 
cells releasing cytokines play a part in altering NK cell function.  
3.3 ENHANCING NK CELL RECOGNITION BY SENSITISING TUMOUR CELLS 
Modulating tumour cells is an attractive approach to increase the chance of cancer 
elimination by the immune system. In paper III we investigated the effect of treatment with 
selenite on NK cell tumour recognition. Selenoproteins have antioxidant properties and are 
thought to prevent cancer development at low doses, but have also been suggested able to 
inhibit carcinogenesis through induced changes in cell growth, signalling and apoptosis (178).  
 
 
Figure 7: HLA-E expression 
decreased on tumour cells after 
selenite treatment. Cell surface level 
of HLA-E on STAV-AB tumour cell 
line, MFI expression compared to 
isotype control (N=7). 
 
 
 
 
After treating a lung cancer cell line with selenite, NK cells degranulated at a higher level and 
also more efficiently killed the target cells. When studying the tumour cells in detail it 
became evident that two surface molecules recognised by NK cells were altered, MIC/A and 
HLA-E (Figure 7). MIC/A binds to the activating NK cell receptor NKG2D, and thus its 
down regulation is unlikely involved in triggering increased NK cell cytotoxicity. HLA-E on 
the other hand, can bind both to the inhibitory receptor NKG2A/CD94 and the activating 
receptor NKG2C/CD94. NKG2A/CD94 is expressed on up to 70-80% of human NK cells 
and a decrease in HLA-E levels would therefore influence the behaviour of a large population 
of NK cells. In our experimental setting we confirmed NKG2A+ NK cells selectively showed 
increased recognition of selenite exposed tumour cells. Measuring total protein and mRNA 
levels showed selenite-induced inhibition of HLA-E expression at a posttranscriptional level, 
and that this was further associated to oxidative stress in the tumour cells.   
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ROS are important in cell signal transduction with roles in differentiation, migration, 
proliferation and apoptosis (179). Hence, oxidative stress can both promote and supress 
cancer progression and the cellular levels of ROS are tightly controlled by antioxidant 
systems. Tumour cells often display increased ROS and antioxidant mechanisms contributing 
to cancer progression and avoidance of apoptosis. Increasing oxidative stress can therefore 
specifically target the malignant cells and tip the balance towards uncontrollable ROS levels 
and cell death. On the other hand, if the increased ROS is still manageable it might instead 
enhance tumour growth. Treatment with compounds such as selenite would therefore require 
careful evaluation of dose levels.  
The HLA-E molecule is transcribed in the majority of cell types in humans, while cell surface 
expression normally is limited to immune cells and endothelial cells (180). However, various 
cancer cells have been reported to over-express HLA-E, e.g. lymphomas, gliomas and 
melanomas (181-183). This could be a specific mechanism to evade NK cell cytotoxicity, or 
reflect a total increase in HLA class I molecules and escape of T cell recognition. Oxidative 
stress caused by selenite may reduce HLA-E levels through general protein reduction, 
prioritising synthesis of cell survival associated proteins. Although promising as cancer 
treatment, further studies are needed to understand the impact of dose levels and the overall 
advantage of selenite administration, as well as the detailed mechanism for HLA-E down-
regulation in tumour cells. 
3.4 NK CELL RESPONSES DURING CANCER TREATMENT 
In paper IV we studied the longitudinal effect on NK cells in follicular lymphoma patients 
treated with monoclonal antibodies. We collected peripheral blood and tumour lymph node 
fine-needle biopsies from previously untreated patients. The samples were collected weekly 
before each first four doses of rituximab (Figure 8).  
 
 
Figure 8: Tumour lymph node and 
peripheral blood NK cells from 
follicular lymphoma patient. Samples 
were collected weekly before each 
rituximab treatment. 
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We found that the NK cell frequency in tumour lymph node (LN) samples was low and in the 
same range as in healthy tonsils. Previous studies have reported NK cells in healthy tonsils 
and lymph nodes to mainly constitute of CD56bright NK cells being CD16 and KIR negative 
(184, 185). The phenotype of the LN-NK cells in our study were to a higher degree CD56dim 
NK cells compared to tonsil controls, furthermore expressing intermediate levels of activating 
and inhibitory receptors and maturation and cytotoxic markers as CD16, KIRs, CD57, 
granzyme A/B and perforin, compared to tonsils and peripheral blood (PB) NK cells. This 
could be due to an on-going immune response towards the proliferating tumour cells.  
In PB we observed a drop in frequency and absolute counts of NK cells after the first 
rituximab administration, confirming previously reported observations (186). NK cells are 
recruited to lymph nodes undergoing an immune response in mice, in a CXCR3 and L-
selectin-dependant manner (187, 188). It is unknown if similar events takes place in humans 
although it is believed that NK cells contribute to the elimination of malignant B-cells in the 
lymph node. We could not detect an overall influx of LN-NK cells, but it is possible that by 
collecting samples weekly we missed important early kinetics. The longitudinal phenotype of 
both LN-NK and PB-NK cells were stable over time regarding CD57, KIRs, CD16, 
granzyme A and perforin. We noted a small increase of NKG2A expression in PB-NK and an 
increase of granzyme B in LN-NK cells.  
 
Figure 9: Proliferative increase in lymph node and peripheral blood NK cells after rituximab treatment. Ki67 
expression in NK cells from patients before and after treatment, and compared to healthy control tonsils (T-ctrl) 
and peripheral blood (PB-ctrl) (Patients N=8, Ctrl N=8).  
 
Ki67 is an intracellular transcription factor found in recently divided or cycling cells (189). 
Staining for this activation marker we found it to be expressed at higher frequencies in LN-
NK cells before treatment than in control tonsil NK cells, while the PB-NK cells had 
comparable levels as healthy control PB-NK cells. After onset of treatment, we detected a 
consistent increase in Ki67 expression in both LN-NK and PB-NK cells (Figure 9). Further 
analysis of Ki67+ LN-NK cells was not possible due to low cell number. In proliferating PB-
NK cells we detected a slightly more differentiated phenotype at day 7 compared to day 0 
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with an increase in CD16, CD57, KIRs, granzyme A and perforin expression. A recent study 
from Rosario et al found enhanced NK cell responses towards lymphoma cells by combining 
rituximab treatment with an IL-15 superagonist, ALT-803 (190). Studying this effect with 
improved killing capacity in mice and in vitro, they furthermore detected increased granzyme 
B and perforin expression in NK cells. Additionally, long-term activation of the IL-15 
receptor with ALT-803 induced proliferation of CD56brightCD16+ NK cells with a maintained 
ADCC function (190). It would be interesting to evaluate to what degree the NK cell 
proliferation we detected in FL patients on rituximab monotherapy is linked to endogenous 
cytokine production, and moreover if the combination of IL-15 and rituximab treatment can 
improve anti-lymphoma responses and survival also in humans.   
We assessed the function of PB-NK cells by re-stimulating cells in vitro with a HLA class I 
negative B-cell line coated with rituximab. After co-incubation the NK cells were stained for 
a degranulation marker (CD107a) and cytokine production (IFNγ). Comparing the 
responding NK cells revealed a decrease in cytokine production in the majority of the patients 
seven days after the first rituximab administration. This altered functionality was moreover 
associated to the proliferative increase, possibly indicating that the onset of cell division 
reprogram the functionality leading to decreased cytokine production. Hyporesponsiveness in 
NK cells following treatment with rituximab has been reported in vitro (191, 192). In these 
short-term models, cytotoxicity was decreased and in one of the studies the NK cell function 
could be restored after 2 days in IL-2. In contrast, our data showed altered cytokine 
production while the degranulation towards rituximab-coated targets was less affected. 
Furthermore we found stable or increased levels of the cytotoxic effector molecules 
granzyme A/B and perforin after treatment, suggesting the ability to perform cellular 
cytotoxicity remained intact. The decreased functionality we observe may represent a 
functional exhaustion following the primary in vivo response to rituximab therapy, and if so 
the variation in the in vitro response may hold clues to the efficacy of the therapy.   
A few patients showed an opposite trend with a more stable or increased NK cell function at 
day 7 and beyond. These patients had a weaker proliferative increase after treatment and 
presence of adaptive NK cell subsets expressing NKG2C and CD57. Adaptive NK cells have 
an increased capacity to produce IFNγ, caused by specific demethylation in the IFNγ 
promoter frame in these cells (31, 35-37). In our study, patients having NKG2C+ NK cells 
could theoretically thus already from start be better equipped for cytokine production in 
response to rituximab treatment and explain the functional stability over time.   
Larger studies has to be done in order to link the clinical response to variation in immune 
repertoires, but the in vivo and in vitro responses we observed here may give some 
indications regarding the role of the NK cells during rituximab therapy. 
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4 CONCLUSIONS 
 
Paper I 
o The expression level of DNAM-1 correlates with the education status of NK cells 
o LFA-1 is activated mainly on non-educated NK cell upon cytokine stimulation, while 
inhibitory interactions maintain LFA-1 in an inactive form on educated NK cells 
o Upon contact with target cells, LFA-1 and DNAM-1 is recruited to the 
immunological synapse 
Paper II 
o NK cells in the bone marrow of MDS patients display reduced expression of DNAM-
1 and NKG2D. The degree of receptor downregulation correlates with the frequency 
of malignant blasts in the bone marrow  
o DNAM-1-CD155/CD122 interactions have an important role in NK cell-mediated 
killing of MDS blasts 
o NK cells from MDS patients are functional hypo-responsive and display poor ability 
to recognise CD34+ MDS blasts 
Paper III 
o NK cell-mediated recognition and killing of a mesothelioma tumour cells line are 
increased following pre-treatment of the tumour cells with selenite 
o Selenite induced a dose-dependant decrease in HLA-E expression on mesothelioma 
tumour cells, caused by oxidative stress-induced protein reduction at a 
posttranscriptional level, triggering activation of NKG2A+ NK cells 
Paper IV 
o NK cells in FL tumour lymph node have an intermediate maturation grade compared 
to the immature healthy lymphoid tissue and mature NK cells in peripheral blood 
o NK cells exposed to rituximab display high expression of Ki67, indicative of high 
proliferate activity in vivo one week after treatment, both in lymphoid tissue and 
peripheral blood 
o NK cells in peripheral blood from rituximab-treated FL-patients have an altered 
cytokine production upon in vitro re-stimulation with rituximab-coated targets 
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